LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Bristol-Myers Squibb Co.

Geschlossen

BrancheGesundheitswesen

46.75 2.25

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

45.73

Max

46.79

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.4B

2.5B

Verkäufe

-1.1B

11B

KGV

Branchendurchschnitt

17.384

56.602

EPS

1.8

Dividendenrendite

5.15

Gewinnspanne

21.98

Angestellte

34,100

EBITDA

1.9B

4.5B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+22.79% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

5.15%

2.45%

Nächstes Ergebnis

31. Juli 2025

Nächste Dividendenausschüttung

31. Juli 2025

Nächstes Ex-Dividendendatum

4. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-17B

95B

Vorheriger Eröffnungskurs

44.5

Vorheriger Schlusskurs

46.75

Nachrichtenstimmung

By Acuity

30%

70%

80 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Bristol-Myers Squibb Co. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Apr. 2025, 11:32 UTC

Ergebnisse

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

13. Mai 2025, 16:48 UTC

Akquisitionen, Fusionen, Übernahmen

2seventy bio: Bristol Myers Squibb Completes Acquisition of 2seventy

12. Mai 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. Mai 2025, 18:45 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12. Mai 2025, 17:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12. Mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

7. Mai 2025, 20:09 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

2seventy Bio 1Q Rev $22.9M >TSVT

7. Mai 2025, 20:08 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

2seventy Bio 1Q EPS 1c >TSVT

7. Mai 2025, 20:08 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

2seventy Bio: Tender Offer Related to Bristol Myers Squibb Deal to Expire May 12 Unless Extended

7. Mai 2025, 20:07 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

2seventy Bio: HSR Waiting Period Expired for Sale to Bristol Myers Squibb

29. Apr. 2025, 19:47 UTC

Ergebnisse

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29. Apr. 2025, 15:22 UTC

Ergebnisse

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29. Apr. 2025, 11:46 UTC

Ergebnisse

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29. Apr. 2025, 11:42 UTC

Ergebnisse

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29. Apr. 2025, 11:12 UTC

Ergebnisse

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

28. Apr. 2025, 21:15 UTC

Ergebnisse

Pfizer Reports Earnings as Stock Sits in Doldrums -- Barrons.com

24. Apr. 2025, 21:24 UTC

Top News
Ergebnisse

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. Apr. 2025, 14:15 UTC

Top News
Ergebnisse

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. Apr. 2025, 12:37 UTC

Market Talk
Ergebnisse

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

24. Apr. 2025, 11:17 UTC

Ergebnisse

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

24. Apr. 2025, 11:13 UTC

Top News
Ergebnisse

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

24. Apr. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

24. Apr. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

24. Apr. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

24. Apr. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

24. Apr. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

24. Apr. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

24. Apr. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

24. Apr. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

24. Apr. 2025, 10:59 UTC

Ergebnisse

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

Peer-Vergleich

Kursveränderung

Bristol-Myers Squibb Co. Prognose

Kursziel

By TipRanks

22.79% Vorteil

12-Monats-Prognose

Durchschnitt 56.25 USD  22.79%

Hoch 68 USD

Tief 36 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bristol-Myers Squibb Co. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

20 ratings

5

Buy

14

Halten

1

Sell

Technischer Score

By Trading Central

N/A / 50.57Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

80 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.